期刊
PERSPECTIVES IN BIOLOGY AND MEDICINE
卷 47, 期 1, 页码 100-109出版社
JOHNS HOPKINS UNIV PRESS
DOI: 10.1353/pbm.2004.0004
关键词
-
A unique public/private partnership situated around a pharmaceutical, Merck's Mectizan((R)) donation program stands out as an example of corporate philanthropy in the history of the pharmaceutical industry and provides insight into future public/private partnerships in public health. This paper considers the issues Merck faced in the decision to donate Mectizan (ivermectin) and in the subsequent development of the Mectizan donation program, delineating the moral and financial debates that arose within the company. Corning after almost 15 years of donation, this assessment of the program's strengths and shortcomings suggests how the pharmaceutical industry can better serve as a viable partner in improving international health.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据